An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorNovartis Pharmaceuticals
About this trial
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Eligibility criteria
Qualifiers
Eligibility for Ongoing Pelabresib Treatment
Able to provide signed informed consent, agreeing to all protocol and ICF requirements.
At least 18 years old and legally able to consent in the study's jurisdiction.
Previously enrolled and currently receiving pelabresib in a parent study.
Disqualifiers
Eligibility for Ongoing Pelabresib Treatment
Legally institutionalized or under judicial protection.
Enrolled in another interventional clinical trial (excluding the parent study).
History of hypersensitivity to pelabresib, its excipients, or similar drugs.
Trial design
Treatments tested in this trial
- Pelabresib
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov